[1] Goldman J M, Melo J V. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-64.
[2] Hochhaus A, Larson R A, Guilhot F, Radich J P, Branford S, Hughes T P, Baccarani M, Deininger M W, Cervantes F, Fujihara S, Ortmann C E, Menssen H D, Kantarjian H, O'Brien S G, Druker B J. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 2017; 376: 917-927.
[3] Kantarjian H M, Dixon D, Keating M J, Talpaz M, Walters R S, McCredie K B, Freireich E J. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-6.
[4] Deininger M, Buchdunger E, Druker B J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-53.
[5] Deininger M W, Goldman J M, Melo J V. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-56.
[6] Melo J V, Barnes D J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441-53.
[7] Geary C G. The story of chronic myeloid leukaemia. Br J Haematol 2000; 110: 2-11.
[8] Santos F P, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs 2010; 11: 1450-65.
[9] Portnow J, Badie B, Markel S, Liu A, D'Apuzzo M, Frankel P, Jandial R, Synold T W. A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. Eur J Cancer 2013; 49: 1634-40.
[10] Niwa T, Asaki T, Kimura S. NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights 2007; 2: 93-106.
[11] Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948-54.
[12] Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, Maekawa T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 2008; 32: 980-3.
[13] Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007; 109: 306-14.
[14] Zhang Y K, Zhang G N, Wang Y J, Patel B A, Talele T T, Yang D H, Chen Z S. Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Sci Rep 2016; 6: 25694.
[15] Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007; 109: 306-14.
[16] Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010; 116: 2665-72.
[17] Yang X, Chen G, Chen Z. MicroRNA-200a-3p Is a Positive Regulator in Cardiac Hypertrophy Through Directly Targeting WDR1 as Well as Modulating PTEN/PI3K/AKT/CREB/WDR1 Signaling. J Cardiovasc Pharmacol 2019; 74: 453-461.
[18] Zheng Y, Ouyang Q, Fu R, Liu L, Zhang H, Hu X, Liu Y, Chen Y, Gao N. The cyclohexene derivative MC-3129 exhibits antileukemic activity via RhoA/ROCK1/PTEN/PI3K/Akt pathway-mediated mitochondrial translocation of cofilin. Cell Death Dis 2018; 9: 656.
[19] Cheng Z, Gao W, Fan X, Chen X, Mei H, Liu J, Luo X, Hu Y. Extracellular signal-regulated kinase 5 associates with casein kinase II to regulate GPIb-IX-mediated platelet activation via the PTEN/PI3K/Akt pathway. J Thromb Haemost 2017; 15: 1679-1688.
[20] Luo X, Zhou N, Wang L, Zeng Q, Tang H. Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53. Can J Gastroenterol Hepatol 2019; 2019: 1389653.
[21] Milella M, Falcone I, Conciatori F, Cesta I U, Del C A, Inzerilli N, Nuzzo C M, Vaccaro V, Vari S, Cognetti F, Ciuffreda L. PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol 2015; 5: 24.
[22] Hopkins B D, Hodakoski C, Barrows D, Mense S M, Parsons R E. PTEN function: the long and the short of it. Trends Biochem Sci 2014; 39: 183-90.
[23] Li A, Qiu M, Zhou H, Wang T, Guo W. PTEN, Insulin Resistance and Cancer. Curr Pharm Des 2017; 23: 3667-3676.
[24] Musa J, Orth M F, Dallmayer M, Baldauf M, Pardo C, Rotblat B, Kirchner T, Leprivier G, Grunewald T G. Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis. Oncogene 2016; 35: 4675-88.
[25] Kim Y Y, Von Weymarn L, Larsson O, Fan D, Underwood J M, Peterson M S, Hecht S S, Polunovsky V A, Bitterman P B. Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res 2009; 69: 8455-62.
[26] Cheng C Y, Kao S T, Lee Y C. Ferulic acid ameliorates cerebral infarction by activating Akt/mTOR/4EBP1/Bcl2 antiapoptotic signaling in the penumbral cortex following permanent cerebral ischemia in rats. Mol Med Rep 2019; 19: 792-804.
[27] Nogami A, Okada K, Ishida S, Akiyama H, Umezawa Y, Miura O. Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway. Transl Oncol 2019; 12: 336-349.